Cargando…

Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection

The reasons behind the clinical variability of SARS-CoV-2 infection, ranging from asymptomatic infection to lethal disease, are still unclear. We performed genome-wide transcriptional whole-blood RNA sequencing, bioinformatics analysis and PCR validation to test the hypothesis that immune response-r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sfikakis, Petros P., Verrou, Kleio-Maria, Ampatziadis-Michailidis, Giannis, Tsitsilonis, Ourania, Paraskevis, Dimitrios, Kastritis, Efstathios, Lianidou, Evi, Moutsatsou, Paraskevi, Terpos, Evangelos, Trougakos, Ioannis, Chini, Vasiliki, Manoloukos, Menelaos, Moulos, Panagiotis, Pavlopoulos, Georgios A., Kollias, George, Hatzis, Pantelis, Dimopoulos, Meletios A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523987/ https://www.ncbi.nlm.nih.gov/pubmed/34675930 http://dx.doi.org/10.3389/fimmu.2021.746203

Ejemplares similares

Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications
por: Trougakos, Ioannis P., et al.
Publicado: (2021)

Molecular Epidemiology of SARS-CoV-2 in Greece Reveals Low Rates of Onward Virus Transmission after Lifting of Travel Restrictions Based on Risk Assessment during Summer 2020
por: Kostaki, Evangelia Georgia, et al.
Publicado: (2021)

Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent
por: Papanagnou, Eleni-Dimitra, et al.
Publicado: (2018)

Distinct type I interferon responses between younger women and older men contribute to the variability of COVID-19 outcomes: Hypothesis generating insights from COVID-19 convalescent individuals
por: Mavragani, Clio P., et al.
Publicado: (2022)

Protocol for unbiased, consolidated variant calling from whole exome sequencing data
por: Verrou, Kleio-Maria, et al.
Publicado: (2022)

Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report
por: Tsitsilonis, Ourania E., et al.
Publicado: (2020)

Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity
por: Bagratuni, Tina, et al.
Publicado: (2020)

Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis
por: Trougakos, Ioannis P., et al.
Publicado: (2022)

COVID-19 mRNA vaccine-induced adverse effects: unwinding the unknowns
por: Trougakos, Ioannis P., et al.
Publicado: (2022)

SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response
por: Tsitsilonis, Ourania E., et al.
Publicado: (2021)

Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection
por: Kostopoulos, Ioannis V., et al.
Publicado: (2021)

Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma
por: Papadimitriou, Konstantinos, et al.
Publicado: (2020)

The role of A-to-I RNA editing in infections by RNA viruses: Possible implications for SARS-CoV-2 infection
por: Vlachogiannis, Nikolaos I., et al.
Publicado: (2021)

Non‐lethal proteasome inhibition activates pro‐tumorigenic pathways in multiple myeloma cells
por: Skorda, Aikaterini, et al.
Publicado: (2019)

The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells
por: Papadhimitriou, Stefanos I., et al.
Publicado: (2022)

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis
por: Kastritis, Efstathios, et al.
Publicado: (2018)

Determination of MYD88(L265P) mutation fraction in IgM monoclonal gammopathies
por: Bagratuni, Tina, et al.
Publicado: (2022)

Systematic integration of RNA-Seq statistical algorithms for accurate detection of differential gene expression patterns
por: Moulos, Panagiotis, et al.
Publicado: (2015)

Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection
por: Orologas-Stavrou, Nikolaos, et al.
Publicado: (2020)

Serological testing for SARS-CoV-2: Advancements and future challenges
por: Alexopoulos, Harry, et al.
Publicado: (2023)

Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies
por: Alexopoulos, Harry, et al.
Publicado: (2023)

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy
por: Terpos, Evangelos, et al.
Publicado: (2019)

Interactive Analysis, Exploration, and Visualization of RNA-Seq Data with SeqCVIBE
por: Bothos, Efthimios, et al.
Publicado: (2022)

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2013)

P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY
por: Terpos, Evangelos, et al.
Publicado: (2023)

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
por: Terpos, Evangelos, et al.
Publicado: (2021)

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
por: Terpos, Evangelos, et al.
Publicado: (2021)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
por: Terpos, Evangelos, et al.
Publicado: (2021)

Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis
por: Kastritis, Efstathios, et al.
Publicado: (2021)

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
por: Terpos, Evangelos, et al.
Publicado: (2022)

How I treat elderly patients with plasma cell dyscrasias
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes
por: Kastritis, Efstathios, et al.
Publicado: (2020)

Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop
por: Bagratuni, Tina, et al.
Publicado: (2019)

Autophagy activation can partially rescue proteasome dysfunction‐mediated cardiac toxicity
por: Papanagnou, Eleni‐Dimitra, et al.
Publicado: (2022)

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
por: Terpos, Evangelos, et al.
Publicado: (2022)

Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis
por: Papadopoulos, Dimitris, et al.
Publicado: (2022)

Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients
por: Melea, Pelagia I., et al.
Publicado: (2014)

Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectives
por: Alygizakis, Nikiforos, et al.
Publicado: (2021)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bj5rtav709g5ffi18e6pvo87pr